

wherein $R_1$ is independently selected from the group consisting of H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;

$R_2$ is independently selected from the group consisting of H; ~~hydroxy~~; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

$B_1$ is hydrogen;

$B_2$ is hydrogen; or $B_1$ and $B_2$ are methylene and joined together to form a five or six membered ring;

Y is methylene or carbonyl;

~~Z is selected from the group consisting of aryl; substituted aryl; N-sulfonamido; N-(aryl)sulfonamido; substituted N-(aryl)sulfonamido; arylamido; substituted arylamido; arylureido; substituted arylureido; arylacetamido; substituted arylacetamido; (aryloxy)carbonylamino; substituted (aryloxy)carbonylamino; 2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl; substituted 2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl; 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl; and substituted 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;~~

L is selected from the group consisting of

$C_{1-8}$alkylene; $C_{2-10}$alkenylene; $C_{2-10}$alkynylene; $C_{3-7}$cycloalkylene;

$C_{3-7}$cycloalkyl$C_{1-4}$alkylene;

aryl$C_{1-4}$alkylene;

α-amino$C_{4-7}$alkylene;



(N-methylene)piperidin-4-yl;



(N-methylene)piperazin-4-yl;



(N-methylene)pyrrolidin-3-yl;



(N-methylene)-4-acetyl-piperidin-4-yl;



and (N-methylene)piperidin-4,4-diyl;



Z is selected from the group consisting of

aryl;



N-sulfonamido;



N-(aryl)sulfonamido;



arylamido;



arylureido;



arylacetamido:



(aryloxy)carbonylamino;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;




and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;




$R_3$ is independently selected from the group consisting of $C_{1-6}$ alkyl; substituted $C_{1-8}$alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

$R_4$ is independently selected from the group consisting of hydrogen; $C_{1-8}$alkyl; $C_{1-8}$alkoxy; substitued $C_{1-8}$alkoxy; hydroxy; halogen; cyano; nitro; amino; $C_{1-8}$alkylamino; and $C_{1-8}$dialkylamino;

$R_5$ is independently selected from the group consisting of hydrogen; $C_{1-8}$alkyl; $C_{1-8}$alkylcarbonyl; aroyl; carbamoyl; amidino; $C_{1-8}$alkyl; $C_{1-8}$alkylaminocarbonyl; (arylamino)carbonyl; and aryl$C_{1-8}$ alkylcarbonyl;

$R_6$ is independently selected from hydrogen and $C_{1-8}$alkyl;

n is 1-2;

m is ~~1~~ 0-3;

p is 1-3; and

q is 1-3;

provided that when Z is aryl or heteroaryl, L is (N-methylene)piperazin-4-yl or (N-methylene)-4-acetylpiperidin-4-yl; and when Z is N-sulfonamido or N-(aryl)sulfonamido, L is α-aminoC4-7alkylene, (N-methylene)piperidin-4-yl or (N-methylene)pyrrolidin-3-yl;

and enantiomers, diastereomers and pharamaceutically acceptable salts thereof.

3. (previously presented) A compound of claim 2 selected from the group consisting of:



and

4. (previously presented) A compound of claim 2 selected from the group consisting of:



and

5. (previously presented) A compound of claim 2 selected from the group consisting of:











and



8. (previously presented) A compound of claim 2 selected from the group consisting of:









and



9. (previously presented) A compound of claim 2 selected from the group consisting of:









and



12. (previously presented) A compound of claim 2 selected from the group consisting of:



and

17. (previously presented) A method of treating disorders and diseases associated with NPY receptor subtype 5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

18. (previously presented) A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

19. (previously presented) A pharmaceutical composition according to claim 18 for the treatment of disorders or disease states caused by eating disorders, obesity, bulimia nervosa, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety.